Advancements in Breast Cancer Treatment | PBCC 2024
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer care and research.
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer care and research.
This Viewpoint discusses the ethics of artificial intelligence–generated compassion in cancer care and outlines 4 main points of concern.
Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
AHNS Podcast A podcast brought to you by the American Head and Neck Society Featuring interviews with leaders in head and neck surgery. Now available through at…
Patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with nadofaragene firadenovec experienced lasting responses to the therapy for up to 3 years.
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival…
UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.